因此ctDNA可以作为mBC患者监测临床预后和治疗疗效的指标,并可根据ctDNA特定的变异指导mBC患者的后线治疗。 近日,湖南省肿瘤医院乳腺内科欧阳取长主任团队与吉因加合作的一项研究成果发表在Lancet子刊eClinicalMedicine(IF=17.033),文章题为“Sub...
[1]BursteinHJ, SomerfieldMR, BartonDL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth pactor receptor 2-negative metastatic breast cancer: ASCO guideline update[J]. J Clin Oncol, 2021, 39(35):3959-3977. [2] 国家肿瘤质控中心乳腺癌专家委员...
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2- negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast Cancer Res Treat. 2024;204:237–48. 4. Collins JM, Nords...
human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).ASCO 2024. Abstract LBA1000.
MBC,即Metastatic Breast Cancer的缩写,直译为转移性乳腺癌。这个英文缩写在医学领域特别常见,特别是在英国医学中,其流行度达到了3038。它代表的英文原词是指癌症从原发部位扩散到其他身体部位的乳腺癌形式。MBC在医学文献中频繁出现,如卡培他滨被批准用于治疗结肠直肠癌和乳腺转移癌,这显示出其在临床...
(T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) withprior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)...
近日,湖南省肿瘤医院乳腺内科欧阳取长主任团队与吉因加合作的一项研究成果发表在 Lancet 子刊eClinicalMedicine(IF=17.033),文章题为“Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study”。该研究使用 吉因加1021基因Panel, 对223例后线...
该研究评估了Halaven作为一种三线或多线疗法治疗mBC患者的治疗模式和临床结果,包括三阴性乳腺癌(TNBC)亚型。研究数据最近发表于国际医学期刊《Advances in Therapy》,文章题目为:Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States。
例句 释义: 全部 更多例句筛选 1. abstract: Objective To explore the efficacy and safety of Capecitabine in the maintenance treatment of metastatic breast cancer(MBC). 目的探讨希罗达在转移性乳腺癌(MBC)维持治疗中的疗效及安全性。 www.purji.com©...
[1] Yizi Jin, et al. Results and exploratory biomarker analyses of a phase II study CHANGEABLE: Combination of HX008 and niraparib in germ-line-mutated metastatic breast cancer.ASCO 2024.Abstract 1084 张剑 教授 复旦大学附属肿瘤医院 肿瘤内科主任医师、博导、一期临床研究病房医疗主任 ...